

Drawing on lessons from the COVID-19 pandemic and previous epidemics, France has launched several initiatives aiming at establishing a national research and innovation ecosystem that is optimally prepared for future health crises caused by infectious diseases, and that is fully integrated in the wider European and International Health Security framework

### **2021 - launch of the France 2030 investment plan**

It aims to accelerate France's industrial and technological transition by supporting strategic sectors such as the energy transition, biotechnologies, digital innovation, and industrial sovereignty. Substantial investments are being made to strengthen the country's competitiveness and resilience by 2030.

**The National Acceleration Strategy for "Emerging Infectious Diseases and Nuclear, Radiological, Biological and Chemical (NRBC) Threats"** is the specific pillar of **France 2030** dedicated to support innovation for the response to emerging infectious diseases and pandemics, among other threats. The scientific foundation of the strategy consists of two complementary Priority Research Programmes and Equipment (PEPRs), implemented in close collaboration over a 5-year period:

- PEPR MIE, which concerns the prevention and control of emerging infectious diseases. It has been assigned €70 million in funding by France 2030, and is led by ANRS Emerging Infectious Diseases (ANRS MIE) in collaboration with its various French academic partners;
- [PEPR PREZODE](#), which concerns the prevention of zoonotic emergences (viruses, bacteria or parasites transmitted to humans by animals or insects). It has been assigned €30 million in funding and is led by CIRAD, INRAE and IRD, and operated by ANR.

The PEPR MIE is structured around three strategic priorities:

- Anticipation and prevention of emerging threats, through improved understanding and control of infectious disease emergence, grounded in a *One Health* approach that integrates human, animal, and environmental health.
- Development of medical countermeasures, to improve diagnostic, prevention, and therapeutic capacities for future health emergencies.
- Strategic research and innovation, focused on understanding emergence mechanisms of infectious diseases, and designing innovative countermeasures through multidisciplinary scientific approaches.

### **Expansion of ANRS | Emerging Infectious Diseases (ANRS MIE).**

ANRS has a long-standing history as a major French agency supporting research on HIV/AIDS and viral hepatitis. Following the COVID-19 pandemic, its scope and mandate were significantly broadened to address emerging and re-emerging infectious diseases more widely. Today, ANRS | Emerging Infectious Diseases (ANRS MIE) promotes, coordinates, and funds a comprehensive research agenda aimed at the prevention, detection, and control of infectious disease threats. Its activities span the entire research continuum, from basic and translational research to clinical studies, public health, and the social and human sciences. ANRS MIE supports both long-term preparedness for future epidemics and pandemics, nationally and internationally, as well as the rapid implementation of research programmes in response to health crises.

Since 2021, the agency has strengthened its support in the field of emerging infectious diseases (EIDs) through several key initiatives, including:

i) The establishment of four major platforms dedicated to the demonstration and validation of surveillance tools and countermeasures:

- EMERGEN 2.0, a platform for genomic surveillance and research on emerging pathogens
- Open-RÉMIE, a clinical research platform
- I-REIVAC-Emergence, a clinical research platform
- Obépine, a programme supporting research on wastewater-based surveillance

ii) The establishment of an outbreak research response unit: in the event of an epidemic outbreak caused by the emergence or re-emergence of a pathogen in France or elsewhere in the world, ANRS MIE activates a dedicated multi-level procedure providing a proportionate response to health crises using a decision-making algorithm

iii) The creation of university research schools to foster capacity-building and training in the field of EID

iii) The launch of 15 calls for proposals, 10 calls for application, supporting 151 research projects for a total funding volume of 97,7 million euros

**2024 - A coordination hub for management of health crises – the Center for Health Security (CCS) was established within the Directorate-General for Health (DGS), in the Ministry of Solidarity and Health**

The CCS aims to strengthen ministerial capacities for anticipating, preparing for, and managing health alerts and crises, while also improving the overall organisation of crisis governance. It relies on the expertise of other central government directorates and mobilises the capabilities of key actors across the health security ecosystem, including health agencies, regional health authorities, scientific societies, and healthcare professionals. At the operational level, the Centre for the Regulation and Response to Health and Social Emergencies (CORUSS) has been reinforced and remains the cornerstone of the national response system. The Directorate General of Health (DGS) also works closely with major organisations involved in surveillance and research, such as Santé publique France, ANSES, the Institut Pasteur, IRD, and INRAE.

**2025 - Launch of France Vaccins.** Since 2025, France has launched France Vaccins, backed by substantial governmental and multiyear budgetary commitments, to accelerate translational vaccine research and reinforce national capacity to rapidly develop and deploy vaccines against emerging infectious disease threats.

These national initiatives are closely aligned with actions at the European level—including the *European Partnership for Pandemic Preparedness*, coordinated by ANRS MIE—and with global health security frameworks and coordination mechanisms, such as the World Health Organization’s *Collaborative Open Research Centres (CORCs)*, including the CORC on filoviruses coordinated by ANRS MIE.

**R&I Policies and Strategies**

<p>Country has a dedicated strategy for research and innovation related to pandemic threat?</p>	<p>France has launched a National Acceleration Strategy for “<b>Emerging Infectious Diseases and Nuclear, Radiological, Biological and Chemical (NRBC) Threats</b>” (MIE-MN). Concerning emerging infectious diseases, the strategy is structured around the following components:</p> <ul style="list-style-type: none"> <li>- <b>Understanding, preventing, and controlling the emergence of infectious diseases</b>, through the integration of a <i>One Health</i> approach, recognising the interconnections between human health, animal health and ecosystems.</li> <li>- <b>Development of medical countermeasures</b> to diagnose, protect, and treat human populations in future emerging threats and limit their impact.</li> <li>- <b>A research component</b>, addressing mechanisms of emergence, advancing knowledge on emerging infectious diseases, and supporting the design and evaluation of innovative countermeasures for prevention and clinical management, based on multidisciplinary scientific approaches.</li> <li>- <b>An innovation component</b>, closely articulated with the research pillar, including actions to support technology maturation, technology transfer, collaborative research, and the creation of start-ups, with the objective of accelerating the development of countermeasures.</li> <li>- <b>A component focused on strengthening production capacities for countermeasures</b>, aimed at securing key value chains on national territory, in coordination with initiatives implemented at the European level.</li> <li>- <b>An organisational component for prevention and crisis management</b>, aligned with international initiatives.</li> <li>- <b>A training component</b>, promoting multidisciplinary to develop new, cross-cutting and integrated skills required to support research and innovation efforts.</li> </ul>
<p>R&amp;I strategy URL</p>	<p><a href="https://www.enseignementsup-recherche.gouv.fr/fr/maladies-infectieuses-emergentes-et-menaces-nucleaires-radiologiques-biologiques-et-chimiques-49220">https://www.enseignementsup-recherche.gouv.fr/fr/maladies-infectieuses-emergentes-et-menaces-nucleaires-radiologiques-biologiques-et-chimiques-49220</a></p>

Country has an open science portal with information on publicly financed scientific research? Yes

R&I portal <https://www.ouvrirlascience.fr/national-plan-for-open-science-4th-july-2018/>

Country has R&I webpage on Filoviruses, Mpox, Avian Influenza, Oropouche Virus, COVID-19; Marburg, Ebola, Other WHO viral risks; Antimicrobial resistance (AMR); Chemical, Biological, Radiological and Nuclear (CBRN) threats

Website open science/ open data initiative with respect to pandemic threats, such as COVID-19 open

Name	URL
Emerging Infectious Diseases (EIDs)	<p><a href="https://anrs.fr/en/who-are-we/emergence-programme/">https://anrs.fr/en/who-are-we/emergence-programme/</a>  <a href="https://anrs.fr/en/emergence-units/">https://anrs.fr/en/emergence-units/</a></p>
AMR	<p><a href="https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-associees-aux-soins-et-resistance-aux-antibiotiques/resistance-aux-antibiotiques">https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-associees-aux-soins-et-resistance-aux-antibiotiques/resistance-aux-antibiotiques</a>  <a href="https://ppr-antibiorestance.inserm.fr/fr/">https://ppr-antibiorestance.inserm.fr/fr/</a></p>
CBRN	<p><a href="https://www.gouvernement.fr/maladies-infectieuses-emergentes-menaces-nucleaires-radiologiques-biologiques-et-chimiques">https://www.gouvernement.fr/maladies-infectieuses-emergentes-menaces-nucleaires-radiologiques-biologiques-et-chimiques</a></p>

Chikungunya	<a href="https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-d-origine-tropicale/chikungunya">https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-d-origine-tropicale/chikungunya</a> <a href="https://ansr.fr/en/emergence-units/cellule-emergence-chikungunya/">https://ansr.fr/en/emergence-units/cellule-emergence-chikungunya/</a>
COVID-19	<a href="https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde">https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde</a> <a href="https://ansr.fr/en/emergence-units/covid-19-emergence-unit/">https://ansr.fr/en/emergence-units/covid-19-emergence-unit/</a>
Dengue	<a href="https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-d-origine-tropicale/dengue">https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-d-origine-tropicale/dengue</a>
Filovirus	<a href="https://ansr.fr/en/emergence-units/filovirus-emergence-unit/">https://ansr.fr/en/emergence-units/filovirus-emergence-unit/</a> <a href="https://ansr.fr/en/partnerships/fighiting-e-pidemics-ansr-mie-leads-who-filovirus-corc/">https://ansr.fr/en/partnerships/fighiting-e-pidemics-ansr-mie-leads-who-filovirus-corc/</a>
Influenza	<a href="https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-transmissibles-de-l-animal-a-l-homme/grippe-aviaire">https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-transmissibles-de-l-animal-a-l-homme/grippe-aviaire</a> <a href="https://ansr.fr/en/emergence-units/avian-influenza-ah5n1-emergence-unit/">https://ansr.fr/en/emergence-units/avian-influenza-ah5n1-emergence-unit/</a>
Mpox	<a href="https://sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/monkeypox/cas-groupes-d-infection-par-le-virus-monkeypox">https://sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/monkeypox/cas-groupes-d-infection-par-le-virus-monkeypox</a> <a href="https://ansr.fr/en/emergence-units/cellule-emergence-mpox-drc-2023/">https://ansr.fr/en/emergence-units/cellule-emergence-mpox-drc-2023/</a>
Respiratory diseases	<a href="https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-respiratoires-aigues">https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-respiratoires-aigues</a>
West Nile	<a href="https://ansr.fr/en/emergence-units/west-nile-emergence-unit/">https://ansr.fr/en/emergence-units/west-nile-emergence-unit/</a>
Zika	<a href="https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-d-origine-tropicale/zika">https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-d-origine-tropicale/zika</a>
national plan for open science	<a href="https://www.ouvrirlascience.fr/national-plan-for-open-science-4th-july-2018/">https://www.ouvrirlascience.fr/national-plan-for-open-science-4th-july-2018/</a> <a href="https://www.enseignementsup-recherche.gouv.fr/fr/le-plan-national-pour-la-science-ouverte-2021-2024-vers-une-generalisation-de-la-science-ouverte-en-48525">https://www.enseignementsup-recherche.gouv.fr/fr/le-plan-national-pour-la-science-ouverte-2021-2024-vers-une-generalisation-de-la-science-ouverte-en-48525</a>

Country has coordinating structures to link public health needs and research needs? Yes

Coordinating structures URL <https://www.gouvernement.fr/maladies-infectieuses-emergentes-menaces-nucleaires-radiologiques-biologiques-et-chimiques>

## **R&I Infrastructures**

Country has the following research infrastructure for infectious diseases and outbreaks available, or under construction BSL 3; BSL 4; Emergency intervention units; Clinical trial units; High level isolation units; Open genome deposits for viruses; Reference centres of excellence

Country supporting the participation to the following ESFRI initiatives	EATRIS-ERIC, ECRIN-ERIC, ERINHA, MIRRI, ELIXIR, Euro-BioImaging, Infrafrontier and INSTRUCT ERIC. Additionally, France is playing a leading role in advancing EU-IBISBA towards ERIC status.
---	--

Website network of clinical trials (e.g. to facilitate access to clinical trials) the country is involved in

<https://proact-response.eu/>  
<https://www.covireivac.fr/qui-sommes-nous/un-reseau-dedie-a-linvestigation-clinique-en-vaccinologie/?cn-reloaded=1>  
<https://ansr.fr/en/infrastructures/research-platforms/open-remie-a-national-platform-for-research/>  
<https://pipelineproject.eu/>  
<https://comectproject.org/>  
<https://ecrin.org/>  
<https://www.recoverytrial.net/>  
<https://www.ecraid.eu/>  
<https://www.fcrin.org/>  
[https://www.global-health-edctp3.europa.eu/index\\_en](https://www.global-health-edctp3.europa.eu/index_en)  
<https://www.remapcap.org/>

## **Budget mobilisation mechanisms and funding sources**

### **Basic Research**

url ANRS MIE <https://ansr.fr/fr/financements/>  
 BE READY PARTNERSHIP <https://beready4pandemics.eu/>  
 Agence Nationale de la Recherche (ANR) : <https://anr.fr/fr/>  
 funding for basic research accessible for private sector? yes  
 source of funding Public (research) agencies

### **Applied Research**

url ANRS MIE <https://ansr.fr/fr/financements/>  
 BE READY PARTNERSHIP <https://beready4pandemics.eu/>  
 funding for applied research accessible for private sector? yes  
 source of funding Public (research) agencies

### **Translational Research**

url BE READY PARTNERSHIP <https://beready4pandemics.eu/>  
 funding accessible for private sector? yes  
 source of funding Public (research) agencies

## Clinical Research (in general)

url ANRS MIE <https://anrs.fr/fr/financements/>  
<https://anrs.fr/financements/tous-les-appels-a-projets/appe-a-projets-rech-mie-2025/>  
Ministère de la Santé et de la Prévention, Programme Hospitalier de Recherche Clinique (PHRC): <https://sante.gouv.fr/systeme-de-sante/innovation-et-recherche/l-innovation-et-la-recherche-clinique/appels-a-projets/article/programme-hospitalier-de-recherche-clinique-phrc>

funding accessible for private sector? yes

source of funding Public (research) agencies

phase funded?

## Clinical Research (in pandemic phase)

url ANRS MIE <https://anrs.fr/fr/financements/>  
Ministère de la Santé et de la Prévention, Programme Hospitalier de Recherche Clinique (PHRC): <https://sante.gouv.fr/systeme-de-sante/innovation-et-recherche/l-innovation-et-la-recherche-clinique/appels-a-projets/article/programme-hospitalier-de-recherche-clinique-phrc>

accessible for private sector? yes

source of funding Public (research) agencies

## Innovation Projects

url Secrétariat général pour l'Investissement (SGPI)  
<https://www.gouvernement.fr/secretariat-general-pour-l-investissement-sgpi>  
Banque Publique d'Investissement (BPI France)  
<https://www.bpifrance.fr/nos-actualites/innovation-et-sante-connaissiez-vous-les-actions-de-bpifrance>

funding for innovation projects accessible for industry? Yes

source of funding Public (research) agencies

## Flexible funding in case of emergency

ANRS MIE <https://anrs.fr/fr/financements/>  
BE READY PARTNERSHIP <https://beready4pandemics.eu/>  
ANR <https://anr.fr/fr/detail/call/appe-a-projets-flash-covid-19/>

## R&I actors, authorities and activated processes that are activated in case of a health threat

R&I actors, authorities and ministries involved in case of an outbreak; mobilisation processes of research forces; (existing) national or regional structures that advise governments on R&I during emergencies; administrative procedures to diminish the administrative burden for researchers and funding administrations; assessment of research outputs produced during a crisis; incentives ensuring qualitative scientific dissemination during a crisis; mechanisms to identify promising therapies or medical products for pandemic preparedness that are in the pipeline; international scientific collaboration in case of an outbreak

Name	Brief description	Website
<b>Research Funding &amp; Innovation</b>		
BPI France (Banque Publique d'Investissement – BPI France)	Public investment bank financing innovation and strategic health industries, including biotech and health crisis–relevant capacities.	<a href="https://www.bpifrance.fr">https://www.bpifrance.fr</a>
Agence de l'innovation en santé (AIS)	Agency accelerating health innovation and coordinating strategic investment in health R&I, including preparedness-related domains.	<a href="https://www.agence-innovation-sante.fr">https://www.agence-innovation-sante.fr</a>
ANRS   Maladies infectieuses émergentes (ANRS MIE)	National funding and coordination agency dedicated to research on HIV, viral hepatitis, tuberculosis and emerging infectious diseases.	<a href="https://anrs.fr">https://anrs.fr</a>
Agence française de développement (AFD)	Public development agency financing global health programmes and epidemic preparedness in partner countries.	<a href="https://www.afd.fr">https://www.afd.fr</a>
<b>Research Performing Organisations</b>		
Institut national de la santé et de la recherche médicale (Inserm)	National biomedical research institute leading research in infectious diseases, immunology and clinical research mobilisation during crises.	<a href="https://www.inserm.fr">https://www.inserm.fr</a>

Centre national de la recherche scientifique (CNRS)	Multidisciplinary research organisation contributing to virology, epidemiology, modelling and social sciences relevant to pandemics.	<a href="https://www.cnrs.fr">https://www.cnrs.fr</a>
Institut Pasteur	International biomedical research foundation specialising in infectious diseases and epidemic response research.	<a href="https://www.pasteur.fr">https://www.pasteur.fr</a>
Institut de recherche pour le développement (IRD)	Research institute, includes focus on global health and emerging infectious diseases in low- and middle-income countries.	<a href="https://www.ird.fr">https://www.ird.fr</a>
Centre de coopération internationale en recherche agronomique pour le développement (CIRAD)	Research organisation contributing to One Health approaches, zoonotic disease research and emerging infectious threat preparedness.	<a href="https://www.cirad.fr">https://www.cirad.fr</a>
<b>Public Health &amp; Regulatory Authorities</b>		
-		
Santé publique France	National public health agency responsible for surveillance, epidemiological monitoring and outbreak response.	<a href="https://www.santepubliquefrance.fr">https://www.santepubliquefrance.fr</a>
Haute Autorité de santé (HAS)	Independent authority issuing clinical guidelines, health technology assessments and vaccination recommendations.	<a href="https://www.has-sante.fr">https://www.has-sante.fr</a>
Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)	National health safety agency conducting risk assessment on zoonoses, antimicrobial resistance and environmental health threats.	<a href="https://www.anses.fr">https://www.anses.fr</a>
Haut Conseil de la santé publique (HCSP)	Advisory body providing public health expertise and recommendations during epidemics and health emergencies.	<a href="https://www.hcsp.fr">https://www.hcsp.fr</a>
<b>Government &amp; Strategic Coordination Bodies</b>		
-		
Ministère de la Santé et de la Prévention	Ministry responsible for national health policy and coordination of epidemic preparedness and crisis response.	<a href="https://sante.gouv.fr">https://sante.gouv.fr</a>
Direction générale de l'offre de soins (DGOS)	Directorate overseeing healthcare organisation and hospital preparedness, including crisis coordination.	<a href="https://sante.gouv.fr">https://sante.gouv.fr</a>
Ministère de l'Enseignement supérieur et de la Recherche (MESR – DGR1/DAEI)	Ministry shaping national research and international cooperation policy, including preparedness priorities.	<a href="https://www.enseignementsup-recherche.gouv.fr">https://www.enseignementsup-recherche.gouv.fr</a>
Secrétariat général de la défense et de la sécurité nationale (SGDSN)	Interministerial body coordinating national resilience and biological risk preparedness.	<a href="https://www.sgdsn.gouv.fr">https://www.sgdsn.gouv.fr</a>
<b>Risk &amp; Safety Expertise Bodies</b>		
-		
Institut national de l'environnement industriel et des risques (INERIS)	Public expert body on environmental and technological risks contributing to crisis risk assessment frameworks.	<a href="https://www.ineris.fr">https://www.ineris.fr</a>
Institut de radioprotection et de sûreté nucléaire (IRSN)	National expert organisation on radiological and nuclear risk preparedness and crisis response.	<a href="https://www.irsn.fr">https://www.irsn.fr</a>

Version February 2026



BE READY is responding to the call: HORIZON-HLTH-2021-DISEASE-04-06 "Building a European partnership for pandemic preparedness" under grant agreement 101057795. Starting date: 01.06.2022. | End Date 31.05.2025

BE READY PLUS is responding to the call: HORIZON-HLTH-2024-DISEASE-17 "Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic" under grant agreement 101195079. Starting date: 01.01.2025. | End Date 31.12.2025

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA), under the powers delegated by the European Commission. Neither the European Union nor the granting authority can be held responsible for them. This country profile is based on input received via [https://ec.europa.eu/eusurvey/runner/BEREADY\\_Questionnaire\\_Observatory](https://ec.europa.eu/eusurvey/runner/BEREADY_Questionnaire_Observatory) and desktop research and does not contain any private information